The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2340 participants.

Also called NCT06757764

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,340 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06757764
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06757764. Randomized; triple masking; primary purpose treatment. Start 2025-07-10 (actual); primary completion 2028-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Acronym
CHANGE
Condition
Cerebral Infarction
Condition
Stenosis Artery
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Cilostazol
Intervention (Drug)
Placebo
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Korea Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06757764
Content hash
9b2737ad3868718274049e2b11fc82223fcc1b5b61663fa418d4bf13d858d453